Anticoagulant use from index date to first post-index VTE event
| Overall (N=2299) | ICI (N=605) | Chemo (N=1092) | ICI+chemo (N=602) | |
| Among patients with VTE events during follow-up, n (%) | 404 (17.6) | 82 (13.6) | 206 (18.9) | 116 (19.3) |
| Patients with anticoagulant use, n (%) | 121 (30.0) | 21 (25.6) | 70 (34.0) | 30 (25.9) |
| Treatment duration of medications from index date to first post-index VTE event, mean days | 48.3 | 69.9 | 51.4 | 27.6 |
| Low-molecular-weight heparins, n (%) | 66 (16.3) | 10 (12.2) | 43 (20.9) | 13 (11.2) |
| Warfarin, n (%) | 12 (3.0) | ≤10 (3.7) | ≤10 (3.9) | ≤10 (0.9) |
| Direct-acting oral anticoagulants, n (%) | 59 (14.6) | 10 (12.2) | 33 (16.0) | 16 (13.8) |
| Fondaparinux, n (%) | ≤10 (0.7) | 0 | ≤10 (1.5) | 0 |
ICI, immune checkpoint inhibitor; VTE, venous thromboembolism.